Kennedy Keith sold $166K of CDNA
Kennedy Keith (CFO & COO) sold 2,097 shares of CareDx, Inc. (CDNA) at an average of $79.29 ($78.78–$79.61, $0.17M total) across 2 trades on 2026-11-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider selling can influence sentiment, but 10b5-1 plans are designed to reduce timing-based signaling; absent other news, the effect is usually limited.
Market read
A disclosed insider sale under a 10b5-1 plan, likely to have only modest near-term sentiment impact for CDNA.
What to watch
Traders may overreact to insider-sale headlines; the key nuance is the 10b5-1 plan and the relatively small transaction size versus typical market-moving thresholds.
Background
The article is a SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).
Ticker impact
CareDx CFO and COO Kennedy Keith sold $166,276 of CDNA shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited, with any short-term pressure tied to optics of insider selling rather than new fundamentals.
The filing is a Form 4 insider sale with a stated 10b5-1 plan, which typically reduces signaling value; the dollar amount is also modest for trading impact.
Market effects
Minimal, as this is company-specific insider activity with no sector-wide signal provided.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so price impact could be negligible.
Key entities
- issuerCareDx, Inc.
Company whose shares were sold by an insider under a 10b5-1 plan.
- insiderKennedy Keith
CFO and COO who executed the open-market sale.



